Accuray Incorporated  

(Public, NASDAQ:ARAY)   Watch this stock  
Find more results for ARAY
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.65 - 10.01
Open     -
Vol / Avg. 0.00/1.07M
Mkt cap 534.74M
P/E     -
Div/yield     -
EPS -0.52
Shares 79.75M
Beta 1.25
Inst. own 98%
Nov 20, 2015
Accuray Inc Annual Shareholders Meeting (Estimated) - 12:00PM EST - Add to calendar
Oct 27, 2015
Q1 2016 Accuray Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 20, 2015
Q4 2015 Accuray Inc Earnings Call - Webcast
Aug 20, 2015
Q4 2015 Accuray Inc Earnings Release
Jun 10, 2015
Accuray Inc at Goldman Sachs Healthcare Conference - Webcast
Jun 3, 2015
Accuray Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -5.50% -10.59%
Operating margin -1.45% -5.05%
EBITD margin - 0.09%
Return on average assets -4.81% -8.33%
Return on average equity -29.50% -46.13%
Employees 206 -
CDP Score - -


1310 Chesapeake Ter
SUNNYVALE, CA 94089-1100
United States - Map
+1-408-7164600 (Phone)
+1-408-7164601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports precise, innovative treatment solutions. The Company’s technologies are designed to deliver advanced radiation therapy, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy tailored to the specific needs of each patient. The Company’s suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems (SRS) and stereotactic body radiation therapy systems (SBRT), used to treat multiple types of cancer and tumors throughout the body. The TomoTherapy Systems are used to treat a wide range of cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery.

Officers and directors

Louis J. Lavigne Jr. Independent Chairperson of the Board
Age: 67
Bio & Compensation  - Reuters
Joshua Levine President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Gregory E. Lichtwardt Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Kelly Londy Executive Vice President, Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Alaleh Nouri Senior Vice President, General Counsel, Corporate Secretary
Age: 35
Bio & Compensation  - Reuters
Jack Goldstein Ph.D. Independent Director
Age: 92
Bio & Compensation  - Reuters
Richard R. Pettingill Independent Director
Age: 66
Bio & Compensation  - Reuters
Emad Rizk M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Robert S. Weiss Independent Director
Age: 68
Bio & Compensation  - Reuters
Dennis L. Winger Independent Director
Age: 67
Bio & Compensation  - Reuters